SCHEMBL7974241

SCHEMBL7974241

Cc1ccc(S(=O)(=O)n2cc3c(n2)CCNC3)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
HTR6 P50406 3/20 0.44
MAPT P10636 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
ALDH1A1 P00352 2/20 0.42
LMNA P02545 1/20 0.42
PIK3CD O00329 1/20 0.42
PIK3CA P42336 1/20 0.42
PIK3CB P42338 1/20 0.42
PIK3CG P48736 1/20 0.42
PNMT P11086 2/20 0.40
RECQL P46063 1/20 0.39
TSHR P16473 1/20 0.39
MCOLN3 Q8TDD5 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
PKM P14618 2/20 0.38
MMP2 P08253 1/20 0.37
POLB P06746 1/20 0.37
HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22509402 0.80 HTR6 (0.40) HTR6MAPTPNMTRECQLMCOLN3
SCHEMBL23886602 0.74 PKM (0.47) MEN1KMT2AMAPTSMN1; SMN2ALDH1A1
SCHEMBL25511902 0.74 HSD11B1 (0.41) MEN1KMT2AHTR6SMN1; SMN2ALDH1A1
SCHEMBL25511865 0.73 PIK3CD (0.41) MEN1KMT2AHTR6MAPTSMN1; SMN2
Hydrochloric Acid SCHEMBL23886706 0.73 RAB9A (0.46) MEN1KMT2AMAPTSMN1; SMN2ALDH1A1
SCHEMBL30706270 0.72 CYP2D6 (0.39) MEN1KMT2AMAPTSMN1; SMN2ALDH1A1
SCHEMBL7987717 0.71 HTR6 (0.46) MEN1KMT2AHTR6MAPTALDH1A1
SCHEMBL16841670 0.71 DPP4 (0.43) MEN1KMT2AMAPTSMN1; SMN2ALDH1A1
SCHEMBL12670983 0.71 MEN1 (0.40) MEN1KMT2AMAPTSMN1; SMN2ALDH1A1
SCHEMBL7988560 0.70 KMT2A (0.41) KMT2AMAPTSMN1; SMN2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8377923-B2 Triazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2013-02-19 US disclosed
US-8377923-B2 Triazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2013-02-19 US disclosed
US-20110105460-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2011-05-05 US disclosed
US-20110105460-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2011-05-05 US disclosed
WO-2010001946-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF アステラス製薬株式会社 (JP) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105460-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF HSD11B1, HSD11B2, HSD3B1 MEN1 2484/4885KMT2A 2930/4885HTR6 2214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.